Portal de Periódicos da CAPES

Weight Gain: A Possible Side Effect of All Antiretrovirals

2017; Oxford University Press; Volume: 4; Issue: 4 Linguagem: Inglês

10.1093/ofid/ofx239

2328-8957

Lucia Taramasso, Elena Ricci, Barbara Menzaghi, Giancarlo Orofino, Simone Passerini, Giordano Madeddu, Canio Martinelli, Giuseppe Vittorio De Socio, Nicola Squillace, Stefano Rusconi, Paolo Bonfanti, Antonio Di Biagio, Tiziana Quirino, Paolo Bonfanti, Elena Ricci, Chiara Bellacosa, Paolo Maggi, Leonardo Calza, C Abeli, Barbara Menzaghi, Benedetto Maurizio Celesia, C. Grosso, Anna Maria Stagno, Francesca Vichi, Francesco Mazzotta, Canio Martinelli, Giovanni Penco, Giovanni Cassola, Antonio Di Biagio, Lucia Taramasso, Laura Ambra Nicolini, Chiara Dentone, Chiara Molteni, Loredana Palvarini, Alfredo Scalzini, Laura Carenzi, Giuliano Rizzardini, Laura Valsecchi, Laura Cordier, Stefano Rusconi, Valeria Colombo, Massimo Galli, Marzia Franzetti, Giuseppe Vittorio De Socio, Elena Mazzotta, Giustino Parruti, Giordano Madeddu, Paola Bagella, Manfredi Mura, Raffaella Libertone, Andrea Antinori, Simona Di Giambenedetto, Giancarlo Orofino, Marta Guastavigna, P Caramell,

HIV/AIDS Research and Interventions

Abstract Weight gain and body mass index (BMI) increase are central issues in patients living with HIV who need to minimize the risk of metabolic disease. Information collected through the SCOLTA cohort revealed significant 1-year BMI increase in patients treated with dolutegravir (P = .004), raltegravir (P = .0004), elvitegravir (P = .004), darunavir (P = .0006), and rilpivirine (P = .029). BMI gain correlated with low baseline BMI (P = .002) and older age (P = .0007) in Centers for Disease Control and Prevention stages A/B, with lower BMI (P = .005) and CD4+ T-cell count (P = .007) at enrollment in stage C.